Clopidogrel use in coronary artery disease

References

• Fuster V, Badimon JJ, Badimon L. Clinical–pathological correlations of coronary disease progression and regression. Circulation 86, III1–III11 (1992).
   PubMedGoogle Scholar
• Lewis HD Jr, Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Co-operative Study. N. Engl. J. Med. 309, 396–403 (1983).
   PubMed Web of Science ®Google Scholar
• Cairns JA, Gent M, Singer J et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N. Engl. J. Med. 313, 1369–1375 (1985).
   PubMed Web of Science ®Google Scholar
• Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 336, 827–830 (1990).
   PubMed Web of Science ®Google Scholar
• Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2, 349–360 (1988).
   PubMed Web of Science ®Google Scholar
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med. 338, 1488–1497 (1998).
   PubMed Web of Science ®Google Scholar
• Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N. Engl. J. Med. 339, 436–443 (1998).
   PubMed Web of Science ®Google Scholar
• International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 97, 2386–2395 (1998).
   PubMed Web of Science ®Google Scholar
• Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359, 189–198 (2002).
   PubMed Web of Science ®Google Scholar
• Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98, 734–741 (1998).
   PubMed Web of Science ®Google Scholar
• Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med. 346, 957–966 (2002).
   PubMed Web of Science ®Google Scholar
• Antman EM, Giugliano RP, Gibson CM et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 99, 2720–2732 (1999).
   PubMed Web of Science ®Google Scholar
• Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357, 1905–1914 (2001).
   PubMed Web of Science ®Google Scholar
• Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 355, 337–345 (2000).
   PubMed Web of Science ®Google Scholar
• O’Neill WW, Serruys P, Knudtson M et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N. Engl. J. Med. 342, 1316–1324 (2000).
   PubMed Web of Science ®Google Scholar
• Cannon CP, McCabe CH, Wilcox RG et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 102, 149–156 (2000).
   PubMed Web of Science ®Google Scholar
• Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334, 1084–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med. 339, 1665–1671 (1998).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch. Intern. Med. 159, 2524–2528 (1999).
   PubMed Web of Science ®Google Scholar
• Paradiso-Hardy FL, Angelo CM, Lanctot KL, Cohen EA. Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ 163, 1441–1448 (2000).
   PubMedGoogle Scholar
• Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international co-operative study (CLASSICS). Circulation 102(6), 624–629 (2000).
   PubMed Web of Science ®Google Scholar
• Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 104, 539–543 (2001).
   PubMed Web of Science ®Google Scholar
• Moussa I, Oetgen M, Roubin G et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99, 2364–2366 (1999).
   PubMed Web of Science ®Google Scholar
• Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 101, 590–593 (2000).
   PubMed Web of Science ®Google Scholar
• Lins R, Broekhuysen J, Necciari J, Deroubaix X. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin. Thromb. Hemost. 25(Suppl. 2), 29–33 (1999).
   PubMed Web of Science ®Google Scholar
• Taubert D, Kastrati A, Harlfinger S et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost. 92, 311–316 (2004).
   PubMed Web of Science ®Google Scholar
• McEwen J, Strauch G, Perles P et al. Clopidogrel bioavailability: absence of influence of food or antacids. Semin. Thromb. Hemost. 25(Suppl. 2), 47–50 (1999).
   PubMed Web of Science ®Google Scholar
• Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin. Thromb. Hemost. 25(Suppl. 2), 25–28 (1999).
   PubMed Web of Science ®Google Scholar
• Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin. Thromb. Hemost. 25(Suppl. 2), 15–19 (1999).
   PubMed Web of Science ®Google Scholar
• Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111, 2099–2106 (2005).
   PubMed Web of Science ®Google Scholar
• Montalescot G. Assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation, and ongoing necrosis. Transcatheter Cardiovascular Therapeutics (TCT), Washington DC, USA, October 17–21 (2005).
   Google Scholar
• Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem. 273, 2024–2029 (1998).
   PubMed Web of Science ®Google Scholar
• Hollopeter G, Jantzen HM, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409, 202–207 (2001).
   Google Scholar
• Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J. Clin. Invest. 113, 340–345 (2004).
   PubMed Web of Science ®Google Scholar
• Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J. Am. Coll. Cardiol. 43, 1982–1988 (2004).
   PubMed Web of Science ®Google Scholar
• Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb. Haemost. 88, 488–494 (2002).
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. 45, 246–251 (2005).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908–2913 (2003).
   PubMed Web of Science ®Google Scholar
• Lau WC, Gurbel PA, Watkins PB et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109, 166–171 (2004).
   PubMed Web of Science ®Google Scholar
• Fontana P, DuPont A, Gandrille S et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108, 989–995 (2003).
   PubMed Web of Science ®Google Scholar
• Peeters PA, Crijns HJ, Tamminga WJ, Jonkman JH, Dickinson JP, Necciari J. Clopidogrel, a novel antiplatelet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interaction. Semin. Thromb. Hemost. 25(Suppl. 2), 51–54 (1999).
   PubMedGoogle Scholar
• Forbes CD, Lowe GD, MacLaren M, Shaw BG, Dickinson JP, Kieffer G. Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a β-blocker and a calcium uptake antagonist. Semin. Thromb. Hemost. 25(Suppl. 2), 55–60 (1999).
   PubMedGoogle Scholar
• Lau WC, Waskell LA, Watkins PB et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation 107, 32–37 (2003).
   PubMed Web of Science ®Google Scholar
• Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function – a flow cytometry study. Eur. Heart J. 24, 1744–1749 (2003).
   PubMed Web of Science ®Google Scholar
• Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. 31, 53–59 (2003).
   PubMed Web of Science ®Google Scholar
• Muller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 108, 2195–2197 (2003).
   PubMed Web of Science ®Google Scholar
• Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109, 1335–1338 (2004).
   PubMed Web of Science ®Google Scholar
• Gorchakova O, von Beckerath N, Gawaz M et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur. Heart J. 25, 1898–1902 (2004).
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Midei MG, Malinin AI et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch. Intern. Med. 164, 2051–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Budaj A, Yusuf S, Mehta SR et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 106, 1622–1626 (2002).
   PubMed Web of Science ®Google Scholar
• The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N. Engl. J. Med. 329, 1615–1622 (1993).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Gibson CM, McCabe CH et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 98, 2805–2814 (1998).
   PubMed Web of Science ®Google Scholar
• Ohman EM, Califf RM, Topol EJ et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 82, 781–791 (1990).
   PubMed Web of Science ®Google Scholar
• Ross AM, Coyne KS, Moreyra E et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 97, 1549–1556 (1998).
   PubMed Web of Science ®Google Scholar
• Chesebro JH, Knatterud G, Roberts R et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76, 142–154 (1987).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352, 1179–1189 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. Am. Heart J. 149, 227–233 (2005).
   PubMed Web of Science ®Google Scholar
• Chen Z Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 pateitns with acute myocaridal infarction: randomised placebo-controlled trial. Lancet 366, 1607–1621 (2005).
   Google Scholar
• Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT III et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Frundi D et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111, 2560–2564 (2005).
   PubMed Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 110, 588–636 (2004).
   PubMed Web of Science ®Google Scholar
• Fox KA, Goodman SG, Anderson FA Jr et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur. Heart J. 24, 1414–1424 (2003).
   PubMed Web of Science ®Google Scholar
• Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J. Am. Coll. Cardiol. 40, 231–237 (2002).
   PubMed Web of Science ®Google Scholar
• Fox KA, Mehta SR, Peters R et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110, 1202–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol. 40, 1366–1374 (2002).
   PubMed Web of Science ®Google Scholar
• Silber S, Albertsson P, Aviles FF et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur. Heart J. 26, 804–847 (2005).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am. Heart J. 148, 263–268 (2004).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J. Invasive Cardiol. 16, 169–174 (2004).
   PubMedGoogle Scholar
• Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89, 783–787 (2003).
   PubMed Web of Science ®Google Scholar
• Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am. J. Cardiol. 93, 456–458 (2004).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Winters KJ et al. Randomized comparison of prasugrel (CS-747, LY-640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111, 3366–3373 (2005).
   PubMed Web of Science ®Google Scholar
• Canon CP. DISPERSE-TIMI 33. Presented at the American Heart Assoication. Dallas, Tx, USA (2005).
   Google Scholar